Merck (MRK) reported Q1 FY 2019 earnings of $1.22 per share (versus $1.05 in Q1 FY 2018), beating analysts’ consensus of $1.05.

The company’s quarterly revenues amounted to $10.816 bln (+7.8% y/y), beating analysts’ consensus estimate of $10.452 bln.

The company also issued guidance for FY 2019, projecting EPS of $4.67-4.79 (versus its prior estimate of $4.57-4.72 and analysts’ consensus estimate of $4.68) and revenues of $43.9-45.1 bln (versus its prior estimate of $43.2-44.7 bln and analysts’ consensus estimate of $44.5 bln).

MRK rose to $78.00 (+1.59%) in pre-market trading.